Jagsonpal Pharma Q1 results: PAT up 22% YoY at Rs 132M, buyback announced

Exceptional itemResults View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹230.00

prior close

₹238.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+1.7% vs market

Pharmaceuticals peers, median of 162sector-0.8%+1.9% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+8.3

10m

+6.8

15m

+9.5

30m

+6.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1-0.6+1.7-0.8+1.9

Next day

+0.1+0.5-0.4-0.5+0.6

+2.6+1.9+0.8+0.2+2.4

+2.6+2.3+0.3+0.1+2.5

+4.3+3.6+0.7+0.5+3.9

+3.0+4.0-0.9+0.4+2.6

+1.7+4.0-2.2+1.4+0.3

15d

+1.2+4.9-3.6+0.3+0.9

+4.9+5.9-1.0+1.6+3.3

+3.2+4.8-1.6+2.7+0.5

-6.5pendingpending-2.4-4.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1FY27 standalone results: revenue from operations Rs 822.32M, up 8.8% YoY from Rs 756.12M. Net profit Rs 131.89M versus Rs 107.95M, up 22.2% YoY. PBT at Rs 176.80M. Auditors Walker Chandiok gave an unqualified limited review. Board recommended Rs 4 per share final dividend for FY26. Buyback of up to 16 lakh shares at Rs 250 each (up to Rs 40 crore) approved. Acquired 85% stake in Aequitas Healthcare for Rs 20.8 crore, completed in July 2026.

Likely market impact

Solid profit growth, buyback, and acquisition signal strong capital allocation. Likely positive for shareholders.